Aquatic Capital Boosts Stake in Ultragenyx Pharmaceutical

Institutional investor increases holdings in rare disease biotech company

Mar. 17, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Aquatic Capital Management LLC, an investment firm, increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 79.1% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund now owns 191,458 shares of the biopharmaceutical company's stock, worth approximately $5.76 million.

Why it matters

Ultragenyx is a leading rare disease biotech company focused on developing therapies for genetic disorders. Aquatic Capital's increased stake suggests the firm sees long-term growth potential in Ultragenyx's pipeline and commercial products.

The details

According to the 13F filing, Aquatic Capital Management added 84,559 shares of Ultragenyx to its portfolio during the third quarter. The firm now owns 0.20% of Ultragenyx's outstanding shares. Several other institutional investors and hedge funds also increased their positions in Ultragenyx during the same period, indicating growing institutional interest in the company.

  • Aquatic Capital Management increased its Ultragenyx stake in the third quarter of 2026.

The players

Aquatic Capital Management LLC

An investment firm that has increased its stake in Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

Aquatic Capital's increased investment in Ultragenyx suggests the firm sees strong growth potential in the rare disease biotech company's pipeline and commercial products, underscoring the rising institutional interest in the rare disease therapeutics space.